Summary

1. Step 5 — Clinical pathway View details →
   Secondary Prevention

   Patient has established atherosclerotic cardiovascular disease. This automatically places them on the secondary-prevention pathway — no risk score is needed to classify risk.

2. Step 6 — Cardiovascular risk View details →
   Very High

   Per standard risk stratification, established atherosclerotic cardiovascular disease is automatically classified Very High risk — no numeric score is calculated.

3. Step 7 — LDL-C target View details →
   <1.4 mmol/L

   Very High risk → target <1.4 mmol/L (and ≥50% reduction from baseline where baseline is known).

4. Step 8 — Treatment plan View details →
   Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)

   Maximally tolerated statin + ezetimibe therapy (or documented intolerance) for ≥3 months, still above target — clinically appropriate to consider a PCSK9 inhibitor. This triggers the Swiss Reimbursement Engine.

5. Step 9 — Swiss reimbursement View details →
   Eligible

   All demo reimbursement criteria are met.

Demonstration output based on simplified rules — not clinical advice. Generated 07.11.2026 17:14.